Neuralink’s Blindsight Implant Gains FDA Breakthrough Designation for Vision Restoration
Neuralink’s Blindsight Implant Gains FDA Breakthrough Designation for Vision Restoration Neuralink, the neurotechnology company led by Elon Musk, has
Neuralink’s Blindsight Implant Gains FDA Breakthrough Designation for Vision Restoration
Neuralink, the neurotechnology company led by Elon Musk, has made significant progress in its mission to restore vision for individuals who are blind. The U.S. Food and Drug Administration (FDA) has granted Neuralink’s latest creation, the Blindsight implant, its prestigious “Breakthrough Device” designation. This status is awarded to medical devices that address life-threatening or irreversibly debilitating conditions, signaling the FDA’s commitment to expediting the development of this groundbreaking technology.
Blindsight is designed to restore sight to individuals who have lost their vision entirely, even those who lack functioning optic nerves. The device works by transmitting visual information directly to the brain, provided the visual cortex remains intact. According to Musk, Blindsight can also enable people who have been blind from birth to experience sight for the first time.
The Blindsight device from Neuralink will enable even those who have lost both eyes and their optic nerve to see.
Provided the visual cortex is intact, it will even enable those who have been blind from birth to see for the first time.
To set expectations correctly, the vision… https://t.co/MYLHNcPrw6 pic.twitter.com/RAenDpd3fx
— Elon Musk (@elonmusk) September 17, 2024
In an announcement on social platform X (formerly Twitter), Musk emphasized that while initial vision quality may be similar to early video game graphics, future advancements in the technology could surpass natural human vision, potentially allowing users to see in different spectrums like infrared and ultraviolet.
This achievement marks a crucial step for Neuralink, as the Breakthrough Device designation will help streamline the FDA approval process, bringing the technology closer to clinical trials and eventual use by patients. Blindsight joins Neuralink’s other brain-computer interface technologies, including implants designed to help paralyzed individuals control digital devices using their thoughts(India Today)(NDTV Business).
